Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP

0.00

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ: CRSP) with a Market Outperform and maintains $80 price target.